Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H De Witte

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Alcoholism, Clinical and Experimental Research|October 5, 2001
Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administrationF Lallemand, P H Soubrié, P H De Witte
Occupational Medicine (Oxford, England)|October 11, 2017
Burnout in Belgian physicians and nursesS Vandenbroeck, E Van Gerven, H De Witte, et al.
Frontiers in Immunology|January 19, 2016
Toward Development of iMesenchymal Stem Cells for Immunomodulatory TherapySamantha F H de Witte, Marcella Franquesa, Carla C Baan, et al.
International Journal of Cancer|July 3, 1998
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assayH De Witte, F Sweep, N Brünner, et al.
Expert Review of Clinical Immunology|March 31, 2015
Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic reviewFranka Luk, Samantha F H de Witte, Wichor M Bramer, et al.
The International Journal of Biological Markers|January 1, 1997
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosolsN Grebenschikov, A Geurts-Moespot, H De Witte, et al.
International Journal of Cancer|May 4, 1999
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1)N Grebenschikov, F Sweep, A Geurts, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 15, 2001
Development of quality control preparations for immunocytochemical assessment of urokinase-type plasminogen activatorH de Witte, M van den Hurk, F Sweep, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|May 9, 1998
Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniquesC M Ferrier, W L van Geloof, H H de Witte, et al.
The Netherlands Journal of Medicine|October 22, 2003
Compassionate use programme of irinotecan in colorectal cancer patients in The NetherlandsW W ten Bokkel Huinink, C J van Groeningen, E E Voest, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Alcoholism, Clinical and Experimental Research|October 5, 2001
Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administrationF Lallemand, P H Soubrié, P H De Witte
Occupational Medicine (Oxford, England)|October 11, 2017
Burnout in Belgian physicians and nursesS Vandenbroeck, E Van Gerven, H De Witte, et al.
Frontiers in Immunology|January 19, 2016
Toward Development of iMesenchymal Stem Cells for Immunomodulatory TherapySamantha F H de Witte, Marcella Franquesa, Carla C Baan, et al.
International Journal of Cancer|July 3, 1998
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assayH De Witte, F Sweep, N Brünner, et al.
Expert Review of Clinical Immunology|March 31, 2015
Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic reviewFranka Luk, Samantha F H de Witte, Wichor M Bramer, et al.
The International Journal of Biological Markers|January 1, 1997
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosolsN Grebenschikov, A Geurts-Moespot, H De Witte, et al.
International Journal of Cancer|May 4, 1999
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1)N Grebenschikov, F Sweep, A Geurts, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 15, 2001
Development of quality control preparations for immunocytochemical assessment of urokinase-type plasminogen activatorH de Witte, M van den Hurk, F Sweep, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|May 9, 1998
Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniquesC M Ferrier, W L van Geloof, H H de Witte, et al.
The Netherlands Journal of Medicine|October 22, 2003
Compassionate use programme of irinotecan in colorectal cancer patients in The NetherlandsW W ten Bokkel Huinink, C J van Groeningen, E E Voest, et al.
Pageof 6